Summary
This NIH funding opportunity (PAR-25-145) solicits R01 research grant applications focused on the clinical characterization of adverse sequelae caused by cancer therapies and the development of mechanism-based interventional strategies to address them. Applicants may optionally include clinical trials as part of their proposed research. The opportunity is issued by the National Institutes of Health (HHS-NIH) and remains open for submissions through early 2028, indicating a multi-cycle, standing Program Announcement with Review (PAR).
